Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Psoriasis is a complex chronic immunologically mediated disease that may involve skin, nails, and joints. It is characterized by hyperproliferation, deregulated differentiation, and impaired apoptosis of keratinocytes. Sphingolipids, namely ceramide, sphingosine-1-phosphate, sphingosine, sphingomyelin, and sphinganine-1-phosphate, are signal molecules that may regulate cell growth, immune reactions, and apoptosis. Fifteen patients with psoriasis and seventeen healthy persons were enrolled in the study. Skin samples were taken from psoriatic lesions and non-lesional areas. Tissue concentration of ceramides, sphingosine-1-phosphate, sphingosine, sphingomyelin, and sphinganine-1-phosphate was measured by liquid chromatography. We assessed that all levels of ceramides, sphingosine-1-phosphate, sphingosine, sphingomyelin, and sphinganine-1-phosphate were higher in lesioned psoriatic skin than in non-affected skin. The profile of bioactive lipids in the lesional skin of patients with psoriasis differed significantly from non-involved psoriatic skin and skin in healthy subjects.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378918 | PMC |
| http://dx.doi.org/10.3390/ijms241411336 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus.
Adv Ther
September 2025
Bristol Myers Squibb, Princeton, NJ, 08540, USA.
Background And Objectives: Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, demonstrated efficacy across the primary endpoint and all key secondary endpoints in the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus (SLE). Here, we describe 2 phase 3 trials [POETYK SLE-1 (NCT05617677), POETYK SLE-2 (NCT05620407)] which will assess the efficacy and safety of deucravacitinib in patients with active SLE. These phase 3 trials have been designed to replicate the successful elements of the phase 2 trial, including its glucocorticoid-tapering strategy and disease activity adjudication.
View Article and Find Full Text PDFApremilast treatment of immune-mediated inflammatory skin diseases: a narrative review.
Front Pharmacol
August 2025
Department of Dermatology, Zhongshan Second People's Hospital, Zhongshan, Guangdong, China.
Novel therapeutic approaches on molecular pathways are being developed to treat inflammatory and autoimmune cutaneous dermatoses. Apremilast is an orally administered small-molecule phosphodiesterase 4 (PDE4) inhibitor that upregulates intracellular cyclic 3',5'-adenosine monophosphate (cAMP) levels to mediate a large array of proinflammatory cytokines as well as exerts its anti-inflammatory functions and therapeutic efficacy in skin diseases rather than an immunosuppressive mode of action. Early-phase clinical trials have demonstrated its favorable efficacy such that the United States Food and Drug Administration (USFDA) has approved its use for the treatment of psoriasis, psoriatic arthritis, and Behçet's syndrome.
View Article and Find Full Text PDFScrotal Cellulitis in the Setting of IL-17A Inhibitor Therapy: A Case Report.
Cureus
September 2025
Medicine, University of Arizona College of Medicine, Phoenix, USA.
Ixekizumab, an IL-17A inhibitor, is commonly used to treat moderate-to-severe plaque psoriasis and psoriatic arthritis, with a well-documented risk of mucocutaneous infections, though its role in bacterial infections is less defined. We present the case of a 62-year-old male on ixekizumab who developed scrotal cellulitis with subsequent septic thrombophlebitis, despite no clear entry point. His condition initially improved with broad-spectrum antibiotics, but later worsened, requiring further imaging and multidisciplinary management.
View Article and Find Full Text PDFFABP5 in skin macrophages mediates saturated fat-induced IL-1β signaling in psoriatic inflammation.
Cell Rep
September 2025
Department of Pathology, University of Iowa, Iowa City, IA, USA. Electronic address:
High fat diet (HFD)-induced obesity increases the risk and severity of psoriasis. However, the immunoregulatory effects of different HFDs on psoriasis pathogenesis remains poorly understood. Here, mimicking human dietary fat profiles, four HFDs-saturated, monounsaturated, omega-6, and omega-3 fats-were designed and used to induce obesity in mice.
View Article and Find Full Text PDFIndole-3-Lactic Acid Inhibits Keratinocyte Proliferation Through the Aryl Hydrocarbon Receptor in Psoriasis.
J Dermatol
September 2025
Department of Dermatology, Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Psoriasis is a chronic inflammatory skin disease whose pathogenesis involves dysregulation of the skin microbiota. Multiple studies have revealed alterations in microbial community composition between psoriatic lesions and healthy skin. However, the metabolic pathways of the skin microbiota, particularly those involving tryptophan metabolism, remain poorly understood.
View Article and Find Full Text PDF